CN101730531A - 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 - Google Patents
芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 Download PDFInfo
- Publication number
- CN101730531A CN101730531A CN200880023589A CN200880023589A CN101730531A CN 101730531 A CN101730531 A CN 101730531A CN 200880023589 A CN200880023589 A CN 200880023589A CN 200880023589 A CN200880023589 A CN 200880023589A CN 101730531 A CN101730531 A CN 101730531A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- chemical compound
- independently
- cancer
- separately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 title abstract description 12
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 title abstract description 10
- 125000003983 fluorenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 title abstract description 6
- BMVWCPGVLSILMU-UHFFFAOYSA-N 5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulen-11-one Chemical compound C1CC2=CC=CC=C2C(=O)C2=CC=CC=C21 BMVWCPGVLSILMU-UHFFFAOYSA-N 0.000 title abstract description 5
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 title abstract description 5
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 55
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 47
- 201000011510 cancer Diseases 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 230000014509 gene expression Effects 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 160
- 125000000217 alkyl group Chemical group 0.000 claims description 144
- -1 halogeno-benzyl Chemical group 0.000 claims description 77
- 125000003118 aryl group Chemical group 0.000 claims description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims description 52
- 229910052760 oxygen Inorganic materials 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 229910052799 carbon Inorganic materials 0.000 claims description 47
- 241000124008 Mammalia Species 0.000 claims description 42
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 40
- 125000000304 alkynyl group Chemical group 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 34
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 28
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 27
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 206010027476 Metastases Diseases 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 229910052727 yttrium Inorganic materials 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 230000033228 biological regulation Effects 0.000 claims description 11
- 150000001408 amides Chemical class 0.000 claims description 10
- 208000029742 colonic neoplasm Diseases 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 229910052770 Uranium Inorganic materials 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000009956 adenocarcinoma Diseases 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 229910052720 vanadium Inorganic materials 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 201000008275 breast carcinoma Diseases 0.000 claims description 4
- 208000015768 polyposis Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 101150012509 sub gene Proteins 0.000 claims 2
- 101150111660 53 gene Proteins 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 abstract description 18
- 108060000903 Beta-catenin Proteins 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 15
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 15
- 230000019491 signal transduction Effects 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 239000002585 base Substances 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 40
- 125000004429 atom Chemical group 0.000 description 26
- 150000001721 carbon Chemical group 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 125000001188 haloalkyl group Chemical group 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 125000004104 aryloxy group Chemical group 0.000 description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000004442 acylamino group Chemical group 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 241001597008 Nomeidae Species 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 7
- 150000001336 alkenes Chemical class 0.000 description 7
- 150000001345 alkine derivatives Chemical class 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000005553 heteroaryloxy group Chemical group 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000012797 qualification Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- RFNBPGZNARQUMR-UHFFFAOYSA-N C1=CC=C2C(=NO)C3=CC=CC=C3C(=NO)C2=C1 Chemical compound C1=CC=C2C(=NO)C3=CC=CC=C3C(=NO)C2=C1 RFNBPGZNARQUMR-UHFFFAOYSA-N 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000004423 acyloxy group Chemical group 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 4
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 125000002723 alicyclic group Chemical group 0.000 description 4
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100035695 Gamma-aminobutyric acid receptor-associated protein Human genes 0.000 description 3
- 101710196196 Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- HCUOEKSZWPGJIM-IYNMRSRQSA-N (e,2z)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N\O)\C(N)=O HCUOEKSZWPGJIM-IYNMRSRQSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 2
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005368 heteroarylthio group Chemical group 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000005023 xylyl group Chemical group 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 101710172561 3alpha-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150096411 AXIN2 gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
- 108010003133 Aldo-Keto Reductase Family 1 Member C2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 102100035683 Axin-2 Human genes 0.000 description 1
- 102000001733 Basic Amino Acid Transport Systems Human genes 0.000 description 1
- 108010015087 Basic Amino Acid Transport Systems Proteins 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101710156796 Cornifin Proteins 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 description 1
- 101000711455 Homo sapiens Kinetochore protein Spc25 Proteins 0.000 description 1
- 101000972486 Homo sapiens Laminin subunit alpha-3 Proteins 0.000 description 1
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 1
- 101000775052 Homo sapiens Protein AHNAK2 Proteins 0.000 description 1
- 101000709370 Homo sapiens S-phase kinase-associated protein 2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108010003718 LDL-Receptor Related Protein-Associated Protein Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100022744 Laminin subunit alpha-3 Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102000004019 NADPH Oxidase 1 Human genes 0.000 description 1
- 108090000424 NADPH Oxidase 1 Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 1
- 102100031822 Optineurin Human genes 0.000 description 1
- 101710131459 Optineurin Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102100040479 P2X purinoceptor 2 Human genes 0.000 description 1
- 101710189968 P2X purinoceptor 2 Proteins 0.000 description 1
- 102100040460 P2X purinoceptor 3 Human genes 0.000 description 1
- 101710189970 P2X purinoceptor 3 Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101800001072 Protein 1A Proteins 0.000 description 1
- 102100031838 Protein AHNAK2 Human genes 0.000 description 1
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100034374 S-phase kinase-associated protein 2 Human genes 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 102000037054 SLC-Transporter Human genes 0.000 description 1
- 108091006248 SLC7 Cationic Amino Acid Transporter Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 102100023776 Signal peptidase complex subunit 2 Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- AENJTRPJFHRERX-UHFFFAOYSA-N [O].C1=CC=C2SC=NC2=C1 Chemical compound [O].C1=CC=C2SC=NC2=C1 AENJTRPJFHRERX-UHFFFAOYSA-N 0.000 description 1
- ILAQRZBYOROJAI-UHFFFAOYSA-N [O].C1=COC=N1 Chemical compound [O].C1=COC=N1 ILAQRZBYOROJAI-UHFFFAOYSA-N 0.000 description 1
- RHJFWPOOZFAPEB-UHFFFAOYSA-N [O].C1=CSC=N1 Chemical compound [O].C1=CSC=N1 RHJFWPOOZFAPEB-UHFFFAOYSA-N 0.000 description 1
- MEAHOCBUVFCKNA-UHFFFAOYSA-N [O].C=1C=COC=1 Chemical compound [O].C=1C=COC=1 MEAHOCBUVFCKNA-UHFFFAOYSA-N 0.000 description 1
- SXMUSCUQMMSSKP-UHFFFAOYSA-N [O].C=1C=CSC=1 Chemical compound [O].C=1C=CSC=1 SXMUSCUQMMSSKP-UHFFFAOYSA-N 0.000 description 1
- HQHFTCAKZCPJBC-UHFFFAOYSA-N [O].C=1C=NOC=1 Chemical compound [O].C=1C=NOC=1 HQHFTCAKZCPJBC-UHFFFAOYSA-N 0.000 description 1
- UHJXEQCVCQFFLS-UHFFFAOYSA-N [O].N1=C(N=CC=C1)OC1=NC=CN=C1 Chemical compound [O].N1=C(N=CC=C1)OC1=NC=CN=C1 UHJXEQCVCQFFLS-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940076134 benzene Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 238000005957 chlorosulfonylation reaction Methods 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000010572 single replacement reaction Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- IOKGWQZQCNXXLD-UHFFFAOYSA-N tert-butyl n-(3-bromopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCBr IOKGWQZQCNXXLD-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
本文公开化学剂如芴、蒽、呫吨、二苯并环庚酮和吖啶和类似杂环结构的二磺酰胺衍生物,包括其盐,所述化学剂可用作抗癌和抗肿瘤剂,特别是当此类化学剂调控Wnt/β-联蛋白信号途径的活性和减少细胞如癌细胞中β-联蛋白水平时,或者当化学剂调控包括癌细胞在内的细胞系统中的基因表达水平时,可用作抗癌和抗肿瘤剂,还公开制备此类化学剂的方法,以及含有此类化学剂作为活性成分的药用组合物和用这些药用组合物作为治疗剂的方法。
Description
本申请要求2007年5月10日提交的美国临时申请60/928,592和2007年10月15日提交的60/999,153的优先权,其公开通过引用完全结合到本文中。
发明领域
本发明涉及用于治疗癌症的新化合物及其使用方法的领域。
发明背景
Wnt/β-联蛋白信号途径被认为是癌症的主要信号途径之一,被视为许多肿瘤类型特别是结肠肿瘤的治疗干预的有效目标。
多细胞生物体的细胞具有相互识别和传递信号的能力,有时距离相当远。通过产生由一个细胞产生的信号分子然后与不同细胞上的特异性受体结合,可完成此类信号传递。此类信号途径涉及各种疾病过程,包括癌症。通过受体结合然后增加细胞内β-联蛋白的Wnt信号传递被称为经典(canonical)途径。Wnt蛋白形成高度保守的分泌信号分子家族,所述分子调节细胞与细胞相互作用,涉及癌症的发病机制。Wnt蛋白与细胞表面的Frizzled和LRP家族的受体结合。通过几种胞质中继组分,将信号转导至β-联蛋白,然后进入细胞核,与TCF形成复合物以激活Wnt靶基因的转录。
在这种途径中,Wnt多肽存在于信号细胞表面上,或由细胞释放并最终接触另一个细胞的特异性细胞表面受体。在靶细胞上的此类受体包括Frizzled/LRP受体(LRP=LDL-受体-相关蛋白),它们将信号传递至细胞内蛋白,如β-联蛋白,其通过连续降解(通常由蛋白体介导)通常保持在相当低的稳态水平。这由含有蛋白GSK-3/APC/Axin(GSK-3=糖原合成酶激酶和APC=腺瘤性结肠息肉病)的复合物控制。Wnt结合在靶细胞表面上的结果是抑制β-联蛋白降解,从而使后者蓄积,进入细胞核内,与转录调节剂结合以打开基因。
业已发现促进Wnt信号途径组成型激活的突变可导致癌症。[综述参阅Logan和Nusse,″The Wnt Signaling Pathway in Development andDisease(在发育和疾病中的Wnt信号途径),″在Ann.Rev.Cell Dev. Biol.,20:781-810(2004)中]例如,Axin2突变使个体容易患结肠癌(Lammi等,Am.J.Hum.Genet.,74:1043-50(2004))。再例如,家族性腺瘤性息肉病(FAP),一种以结肠和直肠多发息肉为特征的遗传性疾病,通常由APC(另一种Wnt信号途径蛋白)切断引起,其促进Wnt途径的畸变激活[参阅:Kinzler等,Science,253:661-665(1991)]在结肠癌及其它肿瘤类型中也已发现APC和β-联蛋白突变(综述参阅Giles等,Biochim.Biophys.Acta,1653:1-24(2003))。此外,导致功能丧失的Axin突变可见于肝细胞癌。[参阅:Satoh等,Nat.Genet.,24:245-50(2000)]因此,使Wnt信号和β-联蛋白调控中断的任何突变或其它细胞事件对于癌症的发生很重要。
因为此类致癌事件与β-联蛋白水平提高有关(即β-联蛋白水平独立于Wnt),所以重新建立这种连接或减少β-联蛋白的小的有机化合物或其它药物将有助于减轻癌性过程,可用作抗肿瘤剂。本发明提供降低肿瘤细胞中β-联蛋白水平的采用芴、蒽、呫吨、二苯并环庚酮和吖啶的二磺酰胺衍生物形式的此类药物。
本领域已知具有被芳族胺取代的磺酰胺基的结构上相关的芴和蒽衍生物(参阅如US 2004/0019042)是包含P2X3和P2X2/3的受体的抑制剂,可用于治疗和预防疾病如膀胱过度活动症、遗尿或尿痛。但是,本文显示,可制备新的结构上相关的化合物,用作Wnt/β-联蛋白途径的调节剂。已知β-联蛋白是Wnt信号途径调节剂(参阅Willert和Nusse,Current Opinion in Genetics and Development(遗传和发育的新观点),8:95-102(1998)。
发明简述
本发明提供干扰Wnt信号途径和减低癌细胞中β-联蛋白水平的用于治疗癌症的新化合物,及其合成方法。在具体实施方案中,这些化合物包括降低肿瘤细胞中β-联蛋白水平的芴、蒽、呫吨、二苯并环庚酮和吖啶的二磺酰胺衍生物。
本发明化合物具有式I结构:
式I
其中n=0-2,其中当n=1时,X选自CH2、O、NRA、CO和C=NORA,其中当n=2时,X=CH2
Y=O、S、NORA或NRA
其中RA选自H、烷基、杂烷基、烯基、炔基、环烷基、-C(=O)RB、-C(=O)ORB、-C(=O)NRBRC、-C(=NRB)RC、-NRBRc、杂环烷基、芳基或多芳族、杂芳基、芳基烷基和烷基芳基
其中所述RB和Rc各自独立是H、烷基或杂烷基,
U和V各自独立选自C=O和O=S=O,其中当U是C=O时,V不是C=O,
R1、R2、R3和R4各自独立选自H、烷基、杂烷基、环烷基、芳基环烷基、烯基、炔基、芳基、杂芳基、杂环烷基,所述R1、R2和所述R3、R4可各自独立结合以形成杂环烷基,
R5和R6各自独立选自H、OH、SH、烷氧基、硫代烷氧基、烷基、卤素、CN、CF3、NO2、COORD、CONRDRE、NRDRE、NRDCORE、NRDSO2RE和NRFCONRDRE;
其中RD、RE和RF独立是H、烷基、杂烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、环烷基或杂环烷基;
其中如果X是O、Y是O且U和V都是O=S=O,则NR1R2和NR3R4不相同,其中R1和R3各自独立选自H和低级烷基,其中R2和R4各自独立选自低级烷氧基(低级烷基)、二(低级)烷基氨基(低级)烷基、卤代苄基、吗啉代(低级)烷基,或者NR1R2和NR3R4独立选自哌啶子基、吗啉代、哌嗪-1-基(piperazino)、N-苯基哌嗪-1-基、乙氨基或取代的甘氨酸,
其中当X是(CH2)2、Y是O或NOH且U和V各自是O=S=O时,则R1、R2、R3和R4无一是甲基,
其中当n=0、Y是O或NOH且U和V各自是O=S=O时,则NR1R2和NR3R4不相同,且R1、R2、R3和R4各自独立选自C1-C5烷基、C10烷基、C16烷基、C17烷基、苯基、苄基、萘基、哌嗪-1-基(piperizino)、吡啶基、吡唑基、苯并咪唑基、三唑基;或者NR1R2和NR3R4独立是哌啶子基、吗啉代或哌嗪-1-基,
其中当X是CO、Y是O且U和V各自是O=S=O时,则NR1R2和NR3R4不一样,其中R1、R2、R3和R4各自独立选自甲基、乙基、羟基-C1-C3-烷基、SH、RO、COOH、SO、NH2和苯基;NR1R2和NR3R4独立选自未被取代的哌啶子基、N-甲基哌嗪-1-基或N-甲基高哌嗪-1-基,
其中当X是C=O或C=NOH,Y是O或NOH,U和V各自是O=S=O,R1或R2其中之一和R3或R4其中之一是苯基时,则R1或R2和R3或R4中的另一个不是H或烷基,
包括其所有药学上可接受的盐、酯、酰胺、立体异构体、几何异构体、溶剂化物或前药。
在具体实施方案中,本发明化合物包括表2-13的那些化合物,所述化合物各自或以任何组合构成本发明。
本发明还提供本发明的任何化合物如表1-13的化合物的治疗组合物。
本发明还涉及改善哺乳动物癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的本发明化合物。特别是表1-13化合物的用途。
定义
除非另外明确表示,否则以下术语各自具有所示含义:
“酰基”或“羰基”是羧酸脱除羟基形成的基团(即R-C(=O)-)。优选酰基包括(例如)乙酰基、甲酰基和丙酰基。
术语“碳链”包括任何烷基、烯基、炔基或杂烷基、杂烯基或杂炔基,为直链、环状或其任何组合。如果该链是连接体的一部分且该连接体包含一个或多个环作为核心主链的一部分,为了计算链长,“链”只包括组成指定环的底部或顶部(并非两者都是)的那些碳原子,当环的顶部和底部长度不等时,应当用较短的距离确定链长。如果链包含杂原子作为主链的一部分,那些原子不算碳链长的一部分。
“烷基”指具有1-15个碳原子、优选1-10个碳原子的饱和烃链。无论单独或组合使用,它都指具有1-约30个碳、更优选1-12个碳的任选取代的直链或任选取代的支链饱和烃基。烷基的非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、叔戊基、戊基、己基、庚基、辛基等。
单独或组合的术语“烯基”指任选取代的直链或任选取代的支链烃基,具有一个或多个碳-碳双键且具有2-约30个碳原子,更优选2-约18个碳。烯基的实例包括乙烯基、丙烯基、丁烯基、1,3-丁二烯基等。
单独或组合的术语“炔基”指任选取代的直链或任选取代的支链烃基,具有一个或多个碳-碳三键且具有2-约30个碳原子,更优选2-约12个碳原子、2-约6个碳原子以及具有2-约4个碳原子。炔基的实例包括乙炔基、2-丙炔基、2-丁炔基、1,3-丁二炔基等。
“烯烃”是具有至少1个(优选仅1个)碳-碳双键且具有2-15个碳原子、优选2-10个、更优选2-5个碳原子的烃链。
“炔烃”是具有至少1个(优选仅1个)碳-碳三键且具有2-15个碳原子、优选2-10个、更优选2-5个碳原子的烃链。
烷基、烯烃和炔烃链(总称为“烃链”)可以是直链或支链,可以未被取代或被取代。优选支链烷基、烯烃和炔烃链具有1或2个分支,优选1个分支。优选链是烷基。烷基、烯烃和炔烃链各自可未被取代或被1-4个取代基取代;当被取代时,优选链被单-、二-或三-取代。烷基、烯烃和炔烃链各自可被卤代基、羟基、芳氧基(如苯氧基)、杂芳氧基、酰氧基(如乙酰氧基)、羧基、芳基(如苯基)、杂芳基、环烷基、杂烷基、杂环烷基、螺环、氨基、酰氨基(amido)、酰基氨基(acylamino)、酮基、硫酮基、氰基或其任何组合取代。优选烃基包括甲基、乙基、丙基、异丙基、丁基、乙烯基、烯丙基、丁烯基和exomethylenyl。
“低级烷基”是较短的烷基,如含有1-约6个碳原子的烷基。
而且,本文提到的“低级”烷基、烯烃或炔烃部分(如“低级烷基”)在烷基情况下是由1-10、优选1-8个碳原子组成的链,在烯烃和炔烃情况下是由2-10、优选2-8个碳原子组成的链。
“烷氧基”指具有烃链取代基的氧基团,其中烃链是烷基或烯基(即-O-烷基或-O-烯基)。烷氧基的实例包括甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基、仲丁氧基、叔丁氧基、烯丙氧基等。
“芳基”是芳族烃环。芳环是单环或稠合双环的环系统。单环芳环的环中包含6个碳原子。单环芳环也称为苯环。双环芳环的环中包含8-17个碳原子,优选9-12个碳原子。双环芳环包括其中一个环是芳基且另一个环是芳基、环烷基或杂环烷基的环系统。优选双环芳环包含与5-、6-或7-元环稠合的5-、6-或7-元环。芳环可以未被取代或在环上被1-4个取代基取代。芳基可以被卤代基、氰基、硝基、羟基、羧基、氨基、酰基氨基、烷基、杂烷基、卤代烷基、苯基、芳氧基、烷氧基、杂烷氧基、氨基甲酰基、卤代烷基、亚甲基二氧基、杂芳氧基或其任何组合取代。优选芳环包括萘基、甲苯基、二甲苯基和苯基。最优选芳环基是苯基。
“芳氧基”是具有芳基取代基的氧基团(即-O-芳基)。优选芳氧基包括(例如)苯氧基、萘氧基、甲氧基苯氧基和亚甲基二氧基苯氧基。
“环烷基”指非芳族的饱和或不饱和烃环。环烷基环是单环,或是稠合、螺或桥接双环或多环的环系统。单环的环烷基环在环中包含约3-约12个碳原子,优选3-7个碳原子。双环的环烷基环在环中包含7-17个碳原子,优选7-12个碳原子。优选双环环烷基环包含与5-、6-或7-元环稠合的4-、5-、6-或7-元环。环烷基环可以未被取代或在环上被1-4个取代基取代。环烷基可被卤代基、氰基、烷基、杂烷基、卤代烷基、苯基、酮基、羟基、羧基、氨基、酰基氨基、芳氧基、杂芳氧基或其任何组合取代。优选环烷基环包括环丙基、环戊基、环己基、环庚基、环辛基和环壬基环。
术语“环烷基”还包括环状烷基,包括单环、双环、三环和高级多环烷基,其中各环状部分具有3-约12个碳原子,是3-12元环。环烷基的实例包括环丙基、环丁基、环戊基、环己基等。
术语“环炔基”指环状炔基,包括单环、双环、三环和高级多环炔基,其中各环状部分具有3-约8个碳原子。“低级炔基”指具有2-约6个碳的炔基。
“卤代基”或“卤素”是氟代基、氯代基、溴代基或碘代基。优选卤代基是氟代基、氯代基和溴代基;通常最优选氯代基和氟代基,特别是氟代基。
“卤代烷基”是被一个或多个卤代取代基取代的直链、支链或环状烃。优选C1-C12卤代烷基;更优选C1-C6卤代烷基;还更优选C1-C3卤代烷基。优选卤代取代基是氟代基和氯代基。
“杂原子”是氮、硫或氧原子。包含不止一个杂原子的基团可包含不同的杂原子。
术语“杂烷基(heteroalkyl)、杂烯基和杂炔基”包括任选取代的如上所述烷基、烯基和炔基结构,其中一个或多个骨架链原子选自非碳原子,如氧、氮、硫、磷或其组合。
“杂烷基(heteroalkyl)”是包含碳和至少一个杂原子的饱和或不饱和链,其中没有两个杂原子相邻。杂烷基链的链中包含2-15、优选2-10、更优选2-5个成员原子(碳和杂原子)。例如,烷氧基(即-O-烷基或-O-杂烷基)可包含在杂烷基中。杂烷基链可为直链或支链。优选支链杂烷基具有1或2个分支,优选1个分支。优选饱和杂烷基。不饱和杂烷基具有一个或多个碳-碳双键和/或一个或多个碳-碳三键。优选不饱和杂烷基具有1或2个双键或三键,更优选1个双键。杂烷基链可以未被取代或被1-4个取代基取代。优选取代的杂烷基被单-、二-或三-取代。杂烷基可被低级烷基、卤代烷基、卤代基、羟基、芳氧基、杂芳氧基、酰氧基、羧基、单环芳基、杂芳基、环烷基、杂烷基、杂环烷基、螺环、氨基、酰基氨基、酰氨基、酮基、硫酮基、氰基或其任何组合取代。当将一种基团描述为例如烷基衍生物如“-乙基吡啶”时,破折号“-”表示取代基的连接点。因此,“-乙基吡啶”指通过基团的乙基段连接乙基吡啶,而“乙基吡啶-”指通过吡啶环连接。
“杂芳基”是在环中包含碳原子和1-约6个杂原子的芳环。杂芳环是单环或稠合的双环环系统。单环杂芳环在环中包含约5-约9个成员原子(碳和杂原子),优选5或6个成员原子。双环杂芳环在环中包含8-17个成员原子,优选8-12个成员原子。双环杂芳环包括其中一个环是杂芳基且另一个环是芳基、杂芳基、环烷基或杂烷基、杂环烷基的环系统。优选双环杂芳基环系统包含与5-、6-或7-元环稠合的5-、6-或7-元环。杂芳环可以未被取代或在环上被1-4个取代基取代。杂芳基可被卤代基、氰基、硝基、羟基、羧基、氨基、酰基氨基、烷基、杂烷基、卤代烷基、苯基、烷氧基、芳氧基、杂芳氧基或其任何组合取代。优选杂芳环包括但不限于以下杂芳环:
稠合杂芳基可包含2-4个稠环,连接的环是杂芳环,稠环系统内的其它各环可以是芳族环、杂芳族环、脂族环或杂环族环。术语杂芳基还包括具有5-约12个骨架环原子以及具有5-约10个骨架环原子的单-杂芳基或稠合杂芳基。术语“低级杂芳基”指具有5-约10个骨架环原子的杂芳基,如吡啶基、噻吩基、嘧啶基、吡嗪基、吡咯基或呋喃基。
“杂芳氧基”是具有杂芳基取代基的氧基团(即-O-杂芳基)。优选杂芳氧基包括(例如)吡啶氧基、呋喃氧基、(噻吩)氧基、(噁唑)氧基、(噻唑)氧基、(异噁唑)氧基、嘧啶氧基、吡嗪氧基和苯并噻唑氧基。
“杂环烷基”是环内包含碳原子和1-4(优选1-3)个杂原子的饱和或不饱和环。杂环烷基环并非芳环。杂环烷基环是单环,或是稠合、桥接或螺双环的环系统。单环杂环烷基环在环中包含约3-约9个成员原子(包括碳和杂原子),优选5-7个成员原子。双环杂环烷基环在环中包含7-17个成员原子,优选7-12个成员原子。双环杂环烷基环包含约7-约17个环原子,优选7-12个环原子。双环杂环烷基环可以是稠合、螺或桥接的环系统。优选双环杂环烷基环包含与5-、6-或7-元环稠合的5-、6-或7-元环。杂环烷基环可以未被取代(即包含氢作为环原子的取代基)或被1-4个取代基取代(在碳或杂原子上或两者皆可),所述取代基选自甲基、卤代基、卤代烷基、氰基、羟基、羧基、酮基、硫酮基、氨基、酰基氨基、酰基、酰氨基、烷基(除甲基以外)、杂烷基、卤代烷基、苯基、烷氧基、芳氧基或其任何组合。优选杂环烷基上的取代基包括甲基、乙氧基、卤代基和卤代烷基。杂环烷基环可通过所述杂环烷基环的任何化学上合适的原子连接成更大结构的取代基。优选杂环烷基环包括但不限于以下杂环烷基环:
术语“元环”可包括任何环状结构,包括芳族、杂芳族、脂环族、杂环和多环的稠合环系统,如下描述。术语“元”指构成环的骨架原子数。因此,例如吡啶、吡喃和嘧啶是6-元环,吡咯、四氢呋喃和噻吩是5-元环。
单独或组合的术语“芳基”指6-约20个环原子的任选取代的芳族烃基,包括单-芳环和稠合芳环。稠合芳环基包含2-4个稠环,其中连接的环是芳环,稠环内的其他各环可以是芳族环、杂芳族环、脂环族或杂环族环。而且,术语芳基包括含有6-约12个碳原子以及含有6-约10个碳原子的单-芳环和稠合芳环。芳基的实例包括但不限于苯基、萘基、蒽基、基和苯并芘基环系统。术语“低级芳基”指具有6-约10个骨架环碳的芳基,如苯基和萘基环系统。
术语“杂环基”指含有5-约20个环原子的任选取代的饱和或不饱和非芳环基团,其中一个或多个环原子是杂原子如氧、氮、硫和磷。术语脂环基包括单-杂环和稠合杂环基。稠合杂环基可包含2-4个稠环,其中连接环是杂环,稠合杂环基内的其它各环可以是芳族、杂芳族、脂环族或杂环族。术语杂环族还包括具有5-约12个骨架环原子以及具有5-约10个骨架环原子的单-杂环族和稠合脂环族基团。杂环族的实例包括但不限于四氢呋喃基、苯二氮杂基、四氢吲唑基、二氢喹啉基等。术语“低级杂环族”指具有5-约10个骨架环原子的杂环系统,如二氢吡喃基、吡咯烷基、吲哚基、哌啶基、哌嗪基等。
单独或组合使用的术语“烷基芳基”指其中1个H原子被如上文限定的烷基代替的如上文限定的芳基,如甲苯基、二甲苯基等。
单独或组合的术语“芳基烷基”或“芳烷基”指其中1个H原子被如上文限定的芳基代替的如上文限定的烷基,如苄基、2-苯基乙基等。
术语“杂芳基烷基”指其中1个H原子被如上文限定的杂芳基代替的如上文限定的烷基,其各自可被任选取代,但其中芳基连接于较大的核心结构,烷基为末端部分。
术语“烷基杂芳基”指其中1个H原子被如上文限定的杂芳基代替的如上文限定的烷基,其各自可被任选取代,但其中烷基连接于较大的核心结构,杂芳基为末端部分。
单独或组合的术语“芳氧基”指其中术语芳基如上文限定的芳基醚基。芳氧基的实例包括苯氧基、苄氧基等。
单独或组合的术语“烷硫基”指烷硫基,烷基-S-,其中术语烷基如上文限定。
单独或组合的术语“芳硫基”指芳硫基,芳基-S-,其中术语芳基如上文限定。
术语“杂芳硫基”指基团杂芳基-S-,其中术语杂芳基如上文限定。
术语“酰基”指基团-C(O)R,其中R包括烷基、烯基、炔基、芳基、杂芳基、脂环基、杂环基、芳基烷基或杂芳基烷基,其中烷基、烯基、炔基、芳基、杂芳基、脂环基、杂环基、芳基烷基或杂芳基烷基可被任选取代。
术语“酰氧基”指酯基-OC(O)R,其中R是H、烷基、烯基、炔基、芳基、杂芳基、脂环基、杂环基、芳基烷基或杂芳基烷基,其中烷基、烯基、炔基、芳基、杂芳基、脂环基、杂环基、芳基烷基或杂芳基烷基可被任选取代。
术语“羧基酯”指-C(O)OR,其中R是烷基、芳基或芳基烷基,其中烷基、芳基和芳基烷基可被任选取代。
术语“氨甲酰基”指结构-C(O)NRR′,其中氮连接于羰基碳,R和R′各自独立选自H、烷基、芳基、杂芳基、脂环基、杂环基、芳基烷基和杂芳基烷基,其中烷基、芳基、杂芳基、脂环基、杂环基或芳基烷基可被任选取代。
术语“氧代基”指双键合的氧,以=O表示。
术语“卤素”包括F、Cl、Br和I。
使用“卤代烷基、卤代烯基、卤代炔基和卤代烷氧基”包括被一个或多个氟、氯、溴或碘或其组合取代的如上描述的烷基、烯基、炔基和烷氧基结构。
术语“全卤代烷基、全卤代烷氧基和全卤代酰基”指所有H原子都被氟、氯、溴或碘或其组合取代的如上描述的烷基、烷氧基和酰基。
术语“环烷基、芳基烷基、芳基、杂芳基、脂环基、杂环基、烷基、炔基、烯基、卤代烷基和杂烷基”包括任选取代的环烷基、芳基烷基、芳基、杂芳基、脂环基、杂环基、烷基、炔基、烯基、卤代烷基和杂烷基。
术语“烷基氨基”指基团-NHR1,其中R独立选自烷基。
术语“二烷基氨基“指基团-NRR′,其中R和R′是烷基。
术语“硫醚”指与2个原子共价结合的硫原子;所述硫的正式(formal)氧化状态是(II)。术语“硫代醚”可与术语“硫醚”互换使用。
术语“亚砜”指与3个原子共价结合的硫原子,其中至少1个原子是氧原子;所述硫原子的正式氧化状态是(IV)。
术语“砜”指与4个原子共价结合的硫原子,其中至少2个原子是氧原子;所述硫原子的正式氧化状态是(VI)。
术语“任选的”或“任选地”指接着描述的事件或状态可以但不一定发生,该描述既包括该事件或状态发生的情况也包括不发生的情况。例如,“被烷基任选单-或二-取代的芳基”指该烷基可以但不一定存在,或者可能存在1或2个烷基,该描述包括芳基被1或2个烷基取代的情况和芳基不被烷基取代的情况。
“任选取代的”基团可被取代或未被取代。“任选取代的”基团的取代基可包括但不限于独立选自以下基团或其特定亚类的一个或多个取代基:低级烷基、低级烯基、低级炔基、低级芳基、杂芳基、脂环基、杂环基、芳基烷基、杂芳基烷基、低级烷氧基、低级芳氧基、氨基、烷基氨基、二烷基氨基、二芳基烷基氨基、烷硫基、芳硫基、杂芳硫基、氧代基、氧杂基、羰基(-C(O))、羧基酯(-C(O)OR)、氨甲酰基(-C(O)NH2)、羧基、酰氧基、-H、卤代基、-CN、-NO2、-N3、-SH、-OH、-C(O)CH3、全卤代烷基、全卤代烷氧基、全卤代酰基、胍、吡啶基、噻吩、呋喃基、吲哚、吲唑、酯、酰胺、膦酸酯、膦酸、磷酸酯、磷酰胺、磺酸酯、砜、硫酸酯、磺酰胺、氨基甲酸酯、脲、硫脲和硫代酰胺、硫烷基。任选取代的基团可以未被取代(如-CH2CH3)、完全取代(如-CF2CF3)、单取代(如-CH2CH2F)或在完全取代与单取代之间的任何水平取代(如-CH2CF3)。
本发明的一些化合物可包含一个或多个手性中心,因此可存在对映体和非对映体形式。本发明的范围预计包括所有异构体本身,以及顺式和反式异构体混合物、非对映体混合物和对映体(旋光异构体)的外消旋混合物,可以用众所周知的方法分离各种形式,本发明一些实施方案的特征可以是指定对映体或非对映体的纯化或富集物。
“药理组合物”指本文所述一种或多种化合物或其药学上可接受的盐与其它化学组分(如药学上可接受的载体和/或赋形剂)的混合物。药理组合物的目的是便于将化合物给予生物体。
短语“药学上可接受的载体”用于本文指药学上可接受的材料、组合物或溶媒,如液体或固体填充剂、稀释剂、赋形剂、溶剂或包囊材料,用于将主药从一种器官或机体的一部分携带或转运至另一种器官或机体的一部分。每种载体必须“可被接受”指与制剂的其它成分相容且对患者无害。可作为药学上可接受的载体的一些材料实例包括:(1)糖,如乳糖、葡萄糖和蔗糖;(2)淀粉,如玉米淀粉和马铃薯淀粉;(3)纤维素及其衍生物,如羧甲基纤维素钠、乙基纤维素和乙酸纤维素;(4)黄蓍胶粉;(5)麦芽;(6)明胶;(7)滑石粉;(8)赋形剂,如可可豆油和栓蜡;(9)油,如花生油、棉籽油、红花油、芝麻油、橄榄油、玉米油和大豆油;(10)二醇,如丙二醇;(11)多元醇,如甘油、山梨醇、甘露醇和聚乙二醇;(12)酯,如油酸乙酯和月桂酸乙酯;(13)琼脂;(14)缓冲剂,如氢氧化镁和氢氧化铝;(15)海藻酸;(16)无热原水;(17)等渗盐水;(18)林格氏液;(19)乙醇;(20)磷酸盐缓冲液;和(21)用于药用制剂中的其它非毒性相容性物质。生理学上可接受的载体应当对生物体不产生明显刺激性并且不消除给予的化合物的生物活性和特性。
术语“赋形剂”指加至药理学组合物以进一步便于化合物给药的惰性物质。赋形剂的实例包括但不限于碳酸钙、磷酸钙、各种糖类和淀粉类型、纤维素衍生物、明胶、植物油和聚乙二醇。
用于本文时,术语“治疗作用”包括但不限于抑制(完全或部分)增殖性疾病如结肠癌的特征细胞的生长。治疗作用还可包括改善疾病的一种或多种症状(除了细胞团块的细胞生长或大小之外),可包括1)减少细胞数目;2)减小细胞大小;3)抑制(即减慢,优选停止)细胞浸润(即转移)入周围器官内;3)抑制或减慢细胞生长;和/或4)缓解与疾病如癌有关的一种或多种症状。产生此类治疗作用的本文公开化合物的任何剂量视为所述化合物的“治疗有效剂量”或“治疗有效量”。
当涉及癌症时,短语“有效量”指在转移或原发性肿瘤进展、大小或生长方面,足以产生所需效应或改善症状或体征的量。代表性的哺乳动物治疗接受者包括小鼠、大鼠、猫、狗和灵长类,包括人。对于具体患者的有效量可不同,取决于以下因素,如正在治疗的疾病、患者的全身健康状况、给药方法、途径和剂量以及副作用的严重度。优选该作用将导致定量改变至少约10%,优选至少20%、30%、50%、70%或甚至90%或更多。当组合时,有效量与组分的组合成比例,其作用不限于各组分单独使用时的作用。
“溶剂化物”是溶质(如金属蛋白酶抑制剂)和溶剂(如水)组合形成的复合物。参阅J.Honig等,The Van Nostrand Chemist′s Dictionary,p.650(1953)。
术语“旋光异构体”、“几何异构体”(如顺式和/或反式异构体)、“立体异构体”和“非对映体”具有公认含义(参阅如Hawley′s CondensedChemical Dictionary,11th Ed.)。举例说明的本发明化合物的具体被保护形式及其它衍生物预计非限制性。其它有用的保护基团、盐形式、前药等的应用在技术人员能力范围之内。
“前药”是在变为活化或完全活化的药物之前必须通过代谢过程发生化学转化的药物形式。前药在其摄入或吸收形式或给药形式时无活性,或活性较小。例如,前药可被消化系统中的细菌分解为产物,其中至少一种将活化成为药物。或者,它可通过全身例如静脉内注射给药,接着代谢为一种或多种活性分子。
用于本文时,术语“IC50”指在测量此类效应的测定中,获得最大效应50%抑制的具体测试化合物的量、浓度或剂量。在本发明的一些方法实施方案中,本发明化合物对正常细胞的“IC50”值可大于对表现增殖性疾病的细胞,如乳癌细胞的“IC50”值。该数值取决于所用测定法。
“标准”指阳性或阴性对照。阴性对照在这里指与癌细胞相反的正常对照,如具有正常细胞相关的Wnt/β-联蛋白途径活性的样品。阴性对照还可包括不含有此类途径的样品。相反,阳性对照含有优选为增殖性疾病如乳癌中所见过度表达相关量的此类途径。对照物可来自细胞或组织样品,或可包含纯化、固定等的配体(或不含配体)。在一些实施方案中,一种或多种对照物可采用诊断“测量杆(dipstick)”的形式。
“选择性靶向”指对一种类型细胞的作用超过另一种,如对于癌细胞和对于非癌细胞的情况下。
发明详述
本发明提供具有式I结构的化合物
式I
其中n=0-2,其中当n=1时,X选自CH2、O、NRA、CO和C=NORA,其中当n=2时,X=CH2
Y=O、S、NORA或NRA,
其中RA选自H、烷基、杂烷基、烯基、炔基、环烷基、-C(=O)RB、-C(=O)ORB、-C(=O)NRBRC、-C(=NRB)RC、-NRBRC、杂环烷基、芳基或多芳族、杂芳基、芳基烷基和烷基芳基其中所述RB和Rc各自独立是H、烷基或杂烷基,
U和V各自独立选自C=O和O=S=O,其中当U是C=O时,V不是C=O,
R1、R2、R3和R4各自独立选自H、烷基、杂烷基、环烷基、芳基环烷基、烯基、炔基、芳基、杂芳基、杂环烷基,所述NR1R2和NR3R4可各自独立形成杂环烷基,
R5和R6各自独立选自H、OH、SH、烷氧基、硫代烷氧基、烷基、卤素、CN、CF3、NO2、COORD、CONRDRE、NRDRE、NRDCORE、NRDSO2RE和NRFCONRDRE;
其中RD、RE和RF独立是H、烷基、杂烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、环烷基或杂环烷基;
前提是如果X是O、Y是O且U和V都是O=S=O,则NR1R2和NR3R4不相同,其中R1和R3各自独立选自H和低级烷基,其中R2和R4各自独立选自低级烷氧基(低级烷基)、二(低级)烷基氨基(低级)烷基、卤代苄基、吗啉代(低级)烷基,或者NR1R2和NR3R4独立选自哌啶子基、吗啉代、哌嗪-1-基、N-苯基哌嗪-1-基、乙氨基或取代的甘氨酸,如果X是(CH2)2、Y是O或NOH且U和V各自是O=S=O,则R1、R2、R3和R4不全是甲基,
如果n=0、Y是O或NOH且U和V各自是O=S=O,则NR1R2和NR3R4不相同,且R1、R2、R3和R4各自独立选自C1-C5烷基、C10烷基、C16烷基、C17烷基、苯基、苄基、萘基、哌嗪-1-基、吡啶基、吡唑基、苯并咪唑基、三唑基;或者NR1R2和NR3R4独立是哌啶子基、吗啉代或哌嗪-1-基,
如果X是CO、Y是O且U和V各自是O=S=O,则NR1R2和NR3R4不相同,其中R1、R2、R3和R4各自独立选自甲基、乙基、羟基-C1-C3-烷基、SH、RO、COOH、SO、NH2和苯基,或者其中不相同的NR1R2和NR3R4其中之一或两者是未被取代的哌啶子基、N-甲基哌嗪-1-基或N-甲基高哌嗪-1-基,
其中当X是C=O或C=NOH,Y是O或NOH,U和V各自是O=S=O,R1或R2其中之一和R3或R4其中之一是苯基时,则R1或R2和R3或R4中的另一个不是H或烷基,
包括其所有药学上可接受的盐、酯、酰胺、立体异构体、几何异构体、溶剂化物或前药。
在另一个实施方案中,本发明提供具有式II结构的化合物
式II
其中R7和R8独立选自H和SO2NR3R4,R7或R8其中之一是氢,或式III化合物
式III
其中R7和R8独立选自H和SO2NR3R4,其中R7和R8其中之一是氢,其中在每个所述式II和III中,其它取代基具有如式I限定的含义。
在本发明的具体实施例中,式I化合物是此类结构,其中A是NR1,或其中A是(CR1R2)m,m=1,或其中A是(CR1R2)m,m=2,R1和R2如本文其它地方限定。
在本发明的具体实施例中,式I化合物是此类结构,其中B是NR1,或其中B是(CR1R2)m,m=1,或其中B是(CR1R2)m,m=2,R1和R2如本文其它地方限定。
在本发明的其它具体实施例中,式I化合物是此类结构,其中C是NR1,或其中C是(CR1R2)m,m=1或m=2,R1和R2如本文其它地方限定。
在本发明的其它具体实施例中,式I化合物是此类结构,其中D是NR1,或其中D是(CR1R2)m,m=1或m=2,R1和R2如本文其它地方限定。
在本发明的另外的具体实施例中,式I化合物是此类结构,其中n=0,使得中间含X的环为5-元环。
在本发明的其它具体实施例中,式I化合物是此类结构,其中X是O且n=1或其中X是O且n=2。
在本发明的具体实施例中,式I化合物是此类结构,其中X是NR1,n=1,或其中X是CO且n=1,或其中X是C=NOR1,n=1,R1如本文其它地方限定。
在本发明的具体实施例中,式I化合物是此类结构,其中X是CR1R2,n=1或其中X是CR1R2,n=2,其中R1和R2如本文其它地方限定。
在本发明的具体实施例中,式I化合物是此类结构,其中Y是O,或其中Y是NR1或其中Y是NOR1,其中R1如本文其它地方限定。
在式I的一个实施方案中,当Y是O时,X不是C=O,当X是C=O时,Y不是O。在单独的实施方案中,Y是O且X是C=O。
在式I的另一个实施方案中,当E是O或NR1时,Y不是NOH或n不是1。在后者的单独实施方案中,当E是O或NR1时,n是1且Y是NOH。
在式I化合物的具体实施例中,U和V各自是O=S=O。后者的另外实施例是其中X是CH2、n=1或2且Y是O或S的化合物,或其中X是CH2、n=1或2且Y是NORA或NRA的化合物,或X是O且Y是O或S的化合物,或其中X是O且Y是NORA或NRA的化合物,或其中X是NRA且Y是O或S的化合物,或其中X是NRA且Y是NORA或NRA的化合物,或其中X是CO且Y=O的化合物,或其中X是CO且Y是NORA或NRA的化合物,或其中X是C=NORA且Y是O的化合物,或其中X是C=NORA且Y是NORA的化合物。
在式I的所有实施方案中,当X是C=O或C=NOH,Y是O或NOH,且U和V各自是O=S=O且R1或R2其中之一和R3或R4其中之一是苯基时,则R1或R2和R3或R4中的另一个不是H或烷基。因此,一种非限制性实施例是如果X是C=O,Y是NOH,U和V各自是O=S=O,R1和R4各自是苯基时,则R2不是H或烷基,R3不是H或烷基。
在式II的一个实施方案中,R1、R2、R3和R4各自独立选自H、烷基、环烷基、烯基和炔基。在另一个此类实施方案中,RA是氢,R1、R2、R3和R4各自独立选自H、烷基、环烷基、烯基和炔基。在其它此类实施方案中,NR1R2和NR3R4各自独立是6-至15-元杂环,优选杂环烷基。
在式II的具体实施方案中,R1、R2、R3和R4各自独立选自H、烷基、环烷基、烯基或炔基。在其它此类实施例中,RA是氢,R1、R2、R3和R4各自独立选自H、烷基、环烷基、烯基或炔基。在其它实施例中,NR1R2和NR3R4独立是6-至15-元杂环,优选在环中含有1个氮的杂环烷基。
在其它实施方案中,本发明化合物是以下环系统其中一种的衍生物,特别是其二磺酰胺衍生物:
此类化合物可被适当取代。
本发明还涉及包括表1-13中化合物在内的化合物的组合物,所述化合物具有式I结构,以治疗有效量存在于药学上可接受的载体中。
式I
其中X=CH2且n=0-2;或O、NRA、CO或C=NORA且n=1Y=O、S、NORA或NRA
其中RA独立选自氢、烷基、杂烷基、烯基、炔基、环烷基、-C(=O)RB、-C(=O)ORB、-C(=O)NRBRc、-C(=NRB)RC、-NRBRC、杂环烷基、芳基或多芳族、杂芳基、芳基烷基和烷基芳基
其中所述RB和RC各自独立是H、烷基、杂烷基,
U和V各自独立选自C=O和O=S=O,如果U是C=O,V不可以是C=O,
R1、R2、R3和R4各自独立选自氢、烷基、杂烷基、环烷基、芳基环烷基、烯基、炔基、芳基、杂芳基、杂环烷基,所述NR1R2和NR3R4各自可独立形成杂环烷基,
R5和R6选自氢、羟基、巯基、烷氧基、硫代烷氧基(thioalkoxy)、烷基、卤素、CN、CF3、NO2、COORD、CONRDRE、NRDRE、NRDCORE、NRDSO2RE和NRFCONRDRE;
其中RD、RE和RF独立是氢、烷基、杂烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、环烷基和杂环烷基;
包括其所有药学上可接受的盐、酯、酰胺、立体异构体、几何异构体、溶剂化物或前药。
所述组合物的化合物还可包含多环环烷基或杂环烷基桥结构(如表所示),所述结构含有总计至多12个原子和至多4个选自N和O的杂原子。
本发明还提供本发明的任何化合物如表1-13的化合物的治疗组合物。
本发明的化合物可采用其药学上可接受的盐、酯、酰胺、立体异构体、几何异构体、溶剂化物或前药的形式。当本发明化合物是立体异构体时,可以是对映体或非对映体。当所述化合物是对映体(或包含手性中心,如手性碳原子)时,用于药用目的的化合物形式可包括对映体或外消旋体,但可优选所述对映体中的一种(例如当对映体中的一种是活化形式或比其它对映体更有活性的情况下)。当所述本发明化合物是几何异构体(如包含以顺式-或反式-构型连接取代基的碳对)时,虽然顺式-形式或反式-形式可优选药用,但顺式-和反式形式的混合物也可用于本发明的方法以达到它们具有所需药效的程度。
“药学上可接受的盐”是在任何酸性(如羧酸)基团形成的阳离子盐,或在任何碱性(如氨基)基团形成的阴离子盐。本领域已知许多此类盐,如描述于WO 87/05297(Johnston等,1987年9月11日公布,通过引用结合到本文中)。合适的酸式盐实例包括乙酸盐、己二酸盐、藻酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、硫酸氢盐、丁酸盐、柠檬酸盐、樟脑酸盐、樟脑磺酸盐、环戊烷丙酸盐、二葡萄糖酸盐、十二烷基硫酸盐、乙磺酸盐、甲酸盐、富马酸盐、葡庚糖酸盐、甘油磷酸盐、乙醇酸盐、半硫酸盐、庚酸盐、己酸盐、盐酸盐、氢溴酸盐、氢碘酸盐、2-羟基乙磺酸盐、乳酸盐、马来酸盐、丙二酸盐、甲磺酸盐、2-萘磺酸盐、烟酸盐、硝酸盐、草酸盐;棕榈酸盐(palmoate)、果胶酯酸盐(pectinate)、过硫酸盐、3-苯基丙酸盐、磷酸盐、苦味酸盐、特戊酸盐、丙酸盐、水杨酸盐、琥珀酸盐、硫酸盐、酒石酸盐、硫氰酸盐、甲苯磺酸盐和十一酸盐。其它酸如草酸虽然本身并非为药学上可接受,但可用于制备盐,所述盐可作为获得本发明化合物及其药学上可接受的酸加成盐的中间体。优选阳离子盐包括碱金属盐(如钠和钾),和碱土金属盐(如镁和钙)和有机盐。优选阴离子盐包括卤化物(如氯化物盐)、磺酸盐、羧酸盐、磷酸盐等。
含有一个或多个酸性官能团的本发明化合物能够与药学上可接受的碱形成药学上可接受的盐。术语“药学上可接受的盐”在这些情况下指本发明化合物的相对无毒性、无机和有机碱加成盐。同样这些盐可在最终分离和纯化化合物时原位制备,或者通过使游离酸形式的纯化化合物单独与合适的碱(如药学上可接受的金属阳离子的氢氧化物、碳酸盐或碳酸氢盐)、与氨或与药学上可接受的有机伯、仲或叔胺反应制备。代表性碱盐或碱土盐包括锂、钠、钾、钙、镁和铝盐等。可使用的一些碱的例示性实例包括氢氧化钠、氢氧化钾、胆碱氢氧化物、碳酸钠、N+(C1-4烷基)4等。可用于形成碱加成盐的代表性有机胺包括乙胺、二乙胺、乙二胺、乙醇胺、二乙醇胺、哌嗪等。本发明还预计使本文公开的化合物的任何碱性含氮基团季铵化。通过这样季铵化可获得可溶解或分散在水或油中的产物。
技术人员熟知此类盐,技术人员能够用专业知识制备任何数目的盐。而且,应理解技术人员可能由于溶解度、稳定性、配制方便性等原因而优选一种盐而不选另一种。对此类盐的确定和优化在技术人员的技能范围内。
另一方面,本发明涉及本发明任何化合物的组合物,优选其中此类化合物以治疗有效量存在于药学上可接受的载体中。此类组合物将通常包含非毒性量(即对治疗而言为安全的量)的此类化合物。
本发明化合物的选择性实例包括但不限于表2-13的任何或所有化合物。任何和所有此类化合物因其在任何和所有本发明方法中的用途而被特别要求保护。在每种所示结构中,通过标记星号(*)的原子连接配体。例如,在表1中,核心结构的硫原子在表中R列标记星号的氮处连接所示R基团。
表1
表2
表3
表4
表5
表6
表7
表8
表9
表10
表11
表12
表13
表14
基因号 | 基因名称 |
1 | 活化转录因子3 |
2 | AHNAK核蛋白2 |
3 | 醛酮还原酶家族1,成员C2(二氢二醇脱氢酶2;胆汁酸结合蛋白;3-α羟基类固醇脱氢酶 |
4 | 含基本的螺-环-螺域,B类,2 |
5 | CD200分子 |
6 | 趋化因子(C-C基序)配体20 |
7 | 染色体13开放读码框15 |
8 | 胞苷脱氨酶 |
9 | 脱氢酶/还原酶(SDR家族)成员9 |
10 | DNA-损伤-诱导性转录子3 |
11 | DnaJ(Hsp40)同源,亚家族B,成员9 |
12 | DnaJ(Hsp40)同源,亚家族C,成员12 |
13 | Dopa脱羧酶(芳族L-氨基酸脱羧酶) |
14 | 双特异性磷酸酶1 |
基因号 | 基因名称 |
15 | 双特异性磷酸酶5 |
16 | 上皮细胞膜蛋白3 |
17 | GABA(A)受体-相关蛋白样1 |
18 | GABA(A)受体-相关蛋白样3 |
19 | 生长分化因子15 |
20 | 过度表达在骨骼肌中的GTP结合蛋白 |
21 | 解旋酶,淋巴特异性 |
22 | 血红素加氧酶(解环)1 |
23 | 组蛋白簇2,H2be |
24 | 假定蛋白MGC 14376 |
25 | IL8 |
26 | 干扰素刺激性核酸外切酶基因20kDa |
27 | 白介素32 |
28 | 白介素8 |
29 | 层粘连蛋白,α3 |
30 | 溶酶体转运(trafficking)调节因子 |
31 | NADPH氧化酶1 |
32 | Optineurin |
33 | 蛋白磷酸酶1,调节(抑制)亚单位15A |
18 | GABA(A)受体-相关蛋白样3 |
34 | PTEN诱导的假定激酶1 |
35 | Ras同源基因家族,成员F(在丝状伪足中) |
36 | 含硬化蛋白(sclerostin)域1 |
37 | sequestosome 1 |
38 | 小富脯氨酸蛋白1A |
39 | 小富脯氨酸蛋白1B(角质蛋白(cornifin)) |
40 | 小富脯氨酸蛋白3 |
41 | 溶质载体家族7,(阳离子氨基酸转运体,y+系统)成员11 |
42 | SPC25,NDC80着丝点复合物组分,同源(酿酒酵母) |
43 | S相激酶相关蛋白2(p45) |
44 | 微管蛋白,α1a |
如上所述,本发明涉及本发明化合物作为药物、特别是作为用于治疗肿瘤的药物的活性成分的用途。因此本发明化合物将存在于药用组合物中,所述药用组合物含有式I或II化合物作为活性成分,与其混合的是药学上可接受的载体和赋形剂,包括本身不诱导产生对接受组合物的个体有害的抗体的任何药物,其给药可不产生过度毒性。药学上可接受的载体包括但不限于液体如水、盐水、甘油和乙醇等,包括可用于形成鼻腔及其它呼吸道喷雾剂或递药至眼部系统的载体。关于药学上可接受的载体、稀释剂及其它赋形剂的全面讨论可参阅REMINGTON′S PHARMACEUTICAL SCIENCES(Mack Pub.Co.,N.J.current edition)。本领域技术人员熟知此类载体的用途,在本文将不再讨论。
如上所述,本发明还涉及预防或治疗与哺乳动物具体基因集合(set)表达水平改变有关的疾病的方法,包括给予所述哺乳动物有效量的本发明化合物。
本发明化合物在需要这样治疗的哺乳动物特别是人中,将具有减少肿瘤特别是原发性肿瘤大小和数量的作用。原发性肿瘤或转移细胞数量的统计学显著性改变将通常为至少约10%、优选20%、30%、50%、70%、90%或更多。
根据本发明,可将本文所述药物与本文所述疾病的其它疗法结合,如其它化疗、放疗、免疫疗法、手术治疗等。还可将本发明化合物与其它药物联合给药,如止痛药、利尿剂、抗利尿剂、抗病毒剂、抗生素、营养补充剂、贫血疗法、凝血疗法、骨疗法,以及精神病学和心理学疗法。
由临床医生(如使用本领域已知可完成治疗或预计将完成治疗的参数或因素)确定合适的治疗剂量。通常,开始的剂量比最佳剂量小一些,然后逐渐小量增加,直至获得与任何不良副作用相比而言所需或最佳的作用。
当然,给予本发明化合物以获得治疗和/或预防作用的具体剂量将由具体情况决定,包括例如给予的具体化合物、给药途径、待治疗疾病和待治疗个体。通常日剂量(单次或分次给药)将包含约0.01mg/kg-约50-100mg/kg体重的本发明活性化合物的剂量水平。优选日剂量通常将为约0.05mg/kg-约25mg/kg,最理想的是约0.1mg/kg-约10mg/kg。虽然本文没有明确叙述,但本领域技术人员用标准程序将很容易确定因素如清除率、半衰期和最大耐受剂量(MTD)。
治疗的有效量将通常使症状控制至少约10%;通常至少约20%;优选至少约30%;更优选至少约50%。或者,迁移的控制将指各种癌细胞类型的迁移或转运受影响。这样将导致例如受影响细胞的数量发生统计学显著性和可定量的改变。这可以是在一段时间或靶区域内吸引的靶细胞数减少。还可监测原发性肿瘤进展的速率、大小或生长。
另一方面,本发明涉及预防或治疗由改变的基因表达调控的疾病的方法,其中所述疾病选自癌、心血管疾病、关节炎、骨质疏松症、炎症、牙周病和皮肤病,包括给予需要这样治疗或预防的哺乳动物治疗有效量的本发明化合物。
在优选实施方案中,本发明涉及在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的本发明化合物,优选其中所述哺乳动物是人。
本发明化合物通常通过调控出现于细胞特别是哺乳动物细胞中的一个或多个基因将发挥治疗作用,所述细胞如癌细胞,优选结肠癌,最优选腺癌。因此,通过确定本发明的一种或多种化合物对基因集合的调控,可用本发明的一种或多种化合物测定或区分这样的基因集合。例如,当发现某基因集合在癌细胞比在其它正常细胞特别是与癌细胞相同组织或器官的正常细胞中上调时,可通过用本发明的一种或多种化合物接触此类基因或含有此类基因的细胞,通过其共同的被调控的特性测定基因集合(基于基因表达的改变,如转录RNA的比率或量或者由所述表达产生的多肽量的改变)。当然,此类调控的程度可与用于接触的所述一种或多种化合物的量有关。此类调控可包括所有测定基因(即该集合的基因)的表达增加,所有该集合基因的表达减少,或该集合基因中一些表达增加而其它表达减少。因此,测试化合物(用于接触基因或含有它们的细胞的化合物)不调控的基因视为非该集合成员。
因此,本发明涉及基因集合,其中所述基因集合与本发明化合物接触的结果是调控所述基因集合各成员的表达。在具体实施方案中,所述接触的结果是所述基因集合各成员的表达增加或者所述接触的结果是表达减少。在另一个优选实施方案中,基因集合存在于细胞中。此类基因集合将通常与具体疾病过程有关,如其中所有基因都由本发明化合物调控的基因集合,其中此类化合物具有具体治疗作用,如作为抗肿瘤剂。
本发明还涉及在哺乳动物中改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的本发明化合物。特别是表1化合物的用途。在选择的实施方案中,所述癌是肉瘤或所述癌是癌瘤。本发明方法针对的具体癌包括但不限于结肠癌、腺癌、直肠癌、结直肠癌、乳癌、肺癌、卵巢癌、腺瘤性息肉病和肝细胞癌中的一种或多种。
本发明还提供根据流程1所示通用合成途径合成式I化合物的便利方法。可通过使相应的芳环系统直接氯磺酰化或通过使合适的磺酸衍生物氯化获得原料磺酰氯1。使化合物1与6或7-元环胺反应以得到仲磺酰胺2。另外可将化合物2转换为衍生物3,其有时可充当前药,所述前药具有改良的物理-化学和药理学特性如水溶性、改良的蛋白结合特性、在血浆中的稳定性、毒性等。
实施例
根据流程1所示通用合成途径用相应的磺酰氯衍生物制备本文公开的大部分化合物。
流程1
以下流程和实施例预计用于举例说明,不限制在附属权利要求书中限定的本发明范围。
流程2
实施例1
2,7-二(氮杂环辛烷-1-基磺酰基)蒽-9,10-二酮(1-27)
使蒽醌-2,7-二磺酰氯(1215mg,3mmole)溶于100mL DCM中。将溶液冷却至-50℃。向该溶液内加入1mL(8mmole)七亚甲亚胺(heptamethyleneimine),接着加入1mL二异丙基乙胺。将反应混合物在室温下搅拌4小时。蒸发溶剂,将残留物用1N HCl处理,滤除,用水洗涤和干燥。使粗材料从氯仿-己烷中结晶,得到1.014g(91%)黄色化合物1-27。H1-NMR(CDCl3):8.70(2H,d,C1和C8),8.47(2H,d,C4和C5),8.22(2H,dd,C3和C6),3.22(8H,m),1.70(20H,m)。
实施例2
2,7-二(氮杂环辛烷-1-基磺酰基)蒽-9,10-二酮二肟(2-22)
将实施例1的产物(1.0g,1.706mmole)、5mL吡啶和盐酸羟胺(1.5g,21.5mmole)在95℃搅拌36小时。蒸发吡啶,将残留物用1N HCl(50mL)搅拌几分钟。将白色产物过滤收集,用水洗涤和干燥。然后用DCM-己烷使粗材料结晶,得到970mg(97%)白色化合物2-22。H1NMR(CDCl3):9.05(1H,dd),8.75(1H,dd),8.35(1H,dd),8.05(1H,dd),7.90(2H,m),3.20(8H,m),1.70(20H,m)。
实施例3
2,7-二(氮杂环辛烷-1-基磺酰基)蒽-9,10-二酮二肟二钠盐(2-22 x 2Na)
将化合物2-22(620mg,1.0mmole)、35mL DCM和2.2mL 1M乙醇钠/乙醇的混合物加热搅拌,直至形成澄清溶液。向溶液内加入100mL醚,对混合物声处理5分钟。将黄色固体产物过滤收集,用醚洗涤和干燥以得到660mg(100%)标题化合物。
实施例4
9,10-二(N′-(3-(二甲基氨基)丙基)-N-乙基氨基甲亚氨酰基氧基亚氨基)-2,7-二(氮杂环辛烷-1-基磺酰基)-9,10-二氢-蒽四盐酸盐(3-18)
将化合物2-22(442mg,0.75mmole)、4mL无水氯仿和400mgEDAC在60℃搅拌1小时。将反应混合物浓缩和用HPLC层析。加入5mL 1N HCl使含有所需产物(MH+=899)的合并流分酸化并蒸发至干。使产物溶于蒸馏水中,冻干得到530mg(68%)白色标题化合物。
流程3
实施例5
9,10-二[(3-氨基丙基)氧基亚氨基]-2,7-二(氮杂环辛烷-1-基磺酰基)-9,10-二氢-蒽(3-24)
向化合物2-22 x 2Na(320mg,0.5mmole)在DMSO(2mL)中的溶液内加入3-溴代丙基氨基甲酸叔丁酯(180mg,0.75mmole),将混合物在室温下搅拌1小时。将水加入反应混合物内,用乙酸乙酯提取沉淀产物。将提取物用硫酸钠干燥,蒸发,用4N HCl/二氧己环(5mL)将残留物搅拌1小时。蒸发溶剂,使残留物溶于甲醇中,用制备HPLC纯化。将含有主产物的流分用盐酸酸化和蒸发。使残留物溶于水中和冻干以得到标题化合物,为二盐酸盐(170mg,2步骤收率为44%)。MS703(MH+)。
实施例6
10-(3-氨基丙基)氧基亚氨基-9-羟基亚氨基-2,7-二(氮杂环辛烷-1-基磺酰基)-9,10-二氢-蒽(3-24)
将实施例5的第二种主产物分离为标题化合物。收率:2步骤后为20%.MS 646(MH+)。
流程4
实施例7
10-甲基-9-氧代-9,10-二氢吖啶-2,7-二磺酰二氯
将10-甲基吖啶-9(10H)-酮(4.2g,20mmole)和氯磺酸(100mL,1.5mole)的混合物回流加热5小时。然后使反应混合物浓缩,冷却至室温,小心地倒在500g冰上。将黄色沉淀产物过滤收集,用水洗涤,干燥以得到8.1g标题化合物。该材料不需纯化用于下一步。
实施例8
2,7-二(3,5-二甲基哌啶-1-基磺酰基)-10-甲基吖啶-9(10H)-酮(11-4)
向来自实施例7的10-甲基-9-氧代-9,10-二氢吖啶-2,7-二磺酰二氯(810mg,2mmole)在THF(20mL)中的溶液内加入3,5-二甲基哌啶(2mL,15mmole),将反应混合物在室温下搅拌6小时。蒸发溶剂,将残留物用1N HCl(50mL)处理和搅拌10分钟。将黄色产物过滤收集,用水和甲醇洗涤并干燥。使粗材料从氯仿-乙醇中结晶以得到900mg(80%)黄色11-4。MS 560(MH+)。
实施例9
2,7-二(3,5-二甲基哌啶-1-基磺酰基)-10-甲基吖啶-9(10H)-硫酮
将化合物11-4(560mg,1mmole)、无水甲苯(10mL)和Lawesson′s试剂(820mg,2mmole)的混合物回流4小时。蒸发除去甲苯。向残留物内加入甲醇(20mL),在室温下搅拌几分钟,将产物过滤收集和干燥以得到500mg标题化合物。MS 576(MH+)。
实施例10
2,7-二(3,5-二甲基哌啶-1-基磺酰基)-9-羟基亚氨基-10-甲基-(9H,10H)-吖啶(12-4)
向2,7-二(3,5-二甲基哌啶-1-基磺酰基)-10-甲基吖啶-9(10H)-硫酮(290mg,0,5mmole)在吡啶(5mL)中的溶液内加入盐酸羟胺(210mg,30mmole),将混合物在100℃搅拌8小时。除去溶剂,用水处理残留物以除去过量羟胺。使粗材料从甲醇-水中结晶以得到245mg(85%)标题化合物。MS 575(MH+)。
实施例11
2,7-二(3,5-二甲基哌啶-1-基磺酰基)-9-(3-二甲基氨基丙基)亚氨基-10-甲基-(9H,10H)-吖啶(12-5)
将2,7-二(3,5-二甲基哌啶-1-基磺酰基)-10-甲基吖啶-9(10H)硫酮(145mg,0.25mmole)、吡啶(5mL)和二甲氨基丙胺(0.125mL,1mmole)的混合物在100℃搅拌4小时。部份蒸发溶剂,加入甲醇使反应产物沉淀。将沉淀物过滤收集,用甲醇洗涤和干燥以得到137mg(85%)标题化合物。MS 644(MH+)。
流程5
实施例12
N2,N7-二(4-叔丁基环己基)-9,10-二氧代-9,10-二氢蒽-2,7-二磺酰胺(1-36):
使蒽醌-2,7-二磺酰氯(10g,24.7mmol)溶于200mL DCM中。将溶液冷却至-50℃。向该溶液内加入4-叔丁基环己胺(8.43g,54mmol),接着加入三乙胺(8.6ml,61.7mmol)。将反应混合物在室温下搅拌4小时。蒸发溶剂,将残留物用MeOH处理,滤除,干燥以得到15g(95%)产物(1-36),为黄色粉状物。
实施例13
N2,N7-二(4-叔丁基环己基)-N2-(3-(二甲基氨基)丙基)-9,10-二氧代-9,10-二氢蒽-2,7-二磺酰胺(13-1)和
N2,N7-二(4-叔丁基环己基)-N2,N7-二(3-(二甲基氨基)丙基)-9,10-二氧代-9,10-二氢蒽-2,7-二磺酰胺(1-70)
在氩气下向磺酰胺(1-36,6.82g,10.61mmol)在无水DMF(100ml)中的冰冷溶液内加入NaH(95.0%,697mg,27.58mmol)。将溶液搅拌5分钟,然后加入3-氯代-N,N-二甲基丙-1-胺盐酸盐(2.18g,13.8mmol)。10分钟后,将反应混合物转移至40℃预热油浴中,搅拌3天。LCMS显示存在单烷基化和二烷基化产物(比率,65∶25),以及未反应的原料。冷却后,将1N NaOH加入反应混合物内,用乙酸乙酯提取。用无水硫酸镁干燥有机相,减压蒸发滤液。将粗混合物用硅胶柱层析纯化。用40%EtOAc/己烷洗脱该柱,回收未反应的原料。单用EtOAc洗脱时获得纯的单烷基化产物(13-1,LCMS,MS 728.0(MH+)),用5%三乙胺/EtOAc作为洗脱剂时分离二烷基化产物(1-70,LCMS,MS 813.2(MH+))。将收集的流分减压蒸发至干以得到13-1(3.02g,53%)和1-70(1.10g,17%)。
流程6
实施例14
N2,N7-二(4-叔丁基环己基)-N2-(3-(二甲基氨基)丙基)-9,10-二(羟基亚氨基)-9,10-二氢蒽-2,7-二磺酰胺(6-1)
用36小时在95℃按照通用程序用单烷基化磺酰胺(13-1,2g,2.7mmol)、过量盐酸羟胺(2.7g,27.5mmol)和吡啶(50ml)制备二肟(6-1)。冷却后,将过量羟胺过滤除去,用吡啶洗涤,将滤液减压蒸发至干。向其内加入过量1N HCl水溶液,使肟沉淀,过滤以收集无色沉淀物和干燥。通过结晶或HPLC进一步纯化以得到作为无色HCl盐的肟(6-1)(1.42g,65%)。
1H NMR(400MHz,DMSO-d6)δ:13.04-13.01(m,1H),12.94-12.89(m,1H),10.48(br s,1H),9.18-9.07(m,1H),8.87-8.78(m,1H),8.40-7.78(m,4H),3.75-3.05(m,16H),2.72(s,6H),1.96-0.76(m,28H)。
实施例15
N2,N7-二(4-叔丁基环己基)-N2,N7-二(3-(二甲基氨基)丙基)-9,10-二(羟基亚氨基)-9,10-二氢蒽-2,7-二磺酰胺(2-65)
按照上文描述的通用程序,用36小时在95℃用相应的蒽醌衍生物(1-70,1g,1.23mmol)、过量盐酸羟胺(1.2g,12.3mmol)和吡啶(25ml)制备作为HCl盐的二肟(2-65)(0.710g,63%)。
1H NMR(400MHz,DMSO-d6)δ:13.09-13.07(m,1H),12.98-12.95(m,1H),9.14-9.08(m,1H),8.89-8.82(m,1H),8.35-7.92(m,4H),3.75-3.04(m,16H),2.72-0.77(m,46H)。
Claims (67)
1.一种具有式I结构的化合物
其中n=0-2,其中当n=1时,X选自CH2、O、NRA、CO和C=NORA,
其中当n=2时,X=CH2
Y是O、S、NORA或NRA
其中RA选自H、烷基、杂烷基、烯基、炔基、环烷基、-C(=O)RB、-C(=O)ORB、-C(=O)NRBRC、-C(=NRB)RC、-NRBRC、杂环烷基、芳基或多芳族、杂芳基、芳基烷基和烷基芳基其中所述RB和RC各自独立是H、烷基或杂烷基,
U和V各自独立选自C=O和O=S=O,其中当U是C=O时,V不是C=O,
R1、R2、R3和R4各自独立选自H、烷基、杂烷基、环烷基、芳基环烷基、烯基、炔基、芳基、杂芳基、杂环烷基,所述NR1R2和NR3R4可各自独立结合以形成杂环烷基,
R5和R6各自独立选自H、OH、SH、烷氧基、硫代烷氧基、烷基、卤素、CN、CF3、NO2、COORD、CONRDRE、NRDRE、NRDCORE、NRDSO2RE和NRFCONRDRE;
其中RD、RE和RF独立是H、烷基、杂烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、环烷基或杂环烷基;
前提是如果X是O、Y是O且U和V都是O=S=O,则NR1R2和NR3R4不相同,R1和R3各自独立选自H和低级烷基,其中R2和R4各自独立选自低级烷氧基(低级烷基)、二(低级)烷基氨基(低级)烷基、卤代苄基、吗啉代(低级)烷基,或者NR1R2和NR3R4独立是哌啶子基、吗啉代、哌嗪-1-基、N-苯基哌嗪-1-基、乙氨基或取代的甘氨酸,其中如果X是(CH2)2、Y是O或NOH且U和V各自是O=S=O,则R1、R2、R3和R4无一是甲基,
其中如果n=0、Y是O或NOH且U和V各自是O=S=O,则NR1R2和NR3R4不相同,R1、R2、R3和R4各自独立选自C1-C5烷基、C10烷基、C16烷基、C17烷基、苯基、苄基、萘基、哌嗪-1-基、吡啶基、吡唑基、苯并咪唑基、三唑基;或者NR1R2和NR3R4独立是哌啶子基、吗啉代或哌嗪-1-基,
其中如果X是CO、Y是O且U和V各自是O=S=O,则NR1R2和NR3R4不相同,其中R1、R2、R3和R4各自独立选自甲基、乙基、羟基-C1-C3-烷基、SH、RO、COOH、SO、NH2和苯基,或者其中不相同的NR1R2和NR3R4其中之一或两者是未被取代的哌啶子基、N-甲基哌嗪-1-基或N-甲基高哌嗪-1-基,
其中当X是C=O或C=NOH,Y是O或NOH,U和V各自是O=S=O,R1或R2其中之一和R3或R4其中之一是苯基时,则R1或R2和R3或R4中的另一个不是H或烷基,
包括其所有药学上可接受的盐、酯、酰胺、立体异构体、几何异构体、溶剂化物或前药。
2.权利要求1的化合物,其中U和V各自是O=S=O。
3.权利要求1的化合物,其中U和V各自是O=S=O,X是CH2,n=1或2,Y是O或S。
4.权利要求1的化合物,其中U和V各自是O=S=O,X是CH2,n=1或2,Y是NORA或NRA。
5.权利要求1的化合物,其中U和V各自是O=S=O,X是O,Y是O或S。
6.权利要求1的化合物,其中U和V各自是O=S=O,X是O,Y是NORA或NRA。
7.权利要求1的化合物,其中U和V各自是O=S=O,X是NRA,Y是O或S。
8.权利要求1的化合物,其中U和V各自是O=S=O,X是NRA,Y是NORA或NRA。
9.权利要求1的化合物,其中U和V各自是O=S=O,X是CO,Y=O。
11.权利要求10的化合物,其中R1、R2、R3和R4各自独立选自H、烷基、环烷基、烯基和炔基。
12.权利要求10的化合物,其中RA是氢,R1、R2、R3和R4各自独立选自H、烷基、环烷基、烯基和炔基。
13.权利要求10的化合物,其中NR1R2和NR3R4各自独立是6-至15-元杂环烷基。
14.权利要求1的化合物,其中U和V各自是O=S=O,X是CO,Y是NORA或NRA。
15.权利要求1的化合物,其中U和V各自是O=S=O,X是C=NORA,Y是O。
16.权利要求1的化合物,其中U和V各自是O=S=O,X是C=NORA,Y是NORA。
18.权利要求17的化合物,其中R1、R2、R3和R4各自独立选自H、烷基、环烷基、烯基或炔基。
19.权利要求17的化合物,其中RA是氢,R1、R2、R3和R4各自独立选自H、烷基、环烷基、烯基或炔基。
20.权利要求17的化合物,其中NR1R2和NR3R4独立是环中含有1个氮的6-至15-元杂环烷基。
21.具有表2所示结构的化合物。
22.具有表3所示结构的化合物。
23.具有表4所示结构的化合物。
24.具有表5所示结构的化合物。
25.具有表6所示结构的化合物。
26.具有表9所示结构的化合物。
27.具有表10所示结构的化合物。
28.具有表11所示结构的化合物。
29.具有表12所示结构的化合物。
30.具有表13所示结构的化合物。
31.一种组合物,所述组合物含有治疗有效量的式I化合物在药学上可接受的载体中,
其中X=CH2且n=0-2;或O、NRA、CO或C=NORA且n=1
Y=O、S、NORA或NRA
其中RA独立选自氢、烷基、杂烷基、烯基、炔基、环烷基、-C(=O)RB、-C(=O)ORB、-C(=O)NRBRC、-C(=NRB)RC、-NRBRC、杂环烷基、芳基或多芳族、杂芳基、芳基烷基和烷基芳基
其中所述RB和RC各自独立是H、烷基、杂烷基,U和V各自独立选自C=O和O=S=O,当U是C=O时,V不可以是C=O,
R1、R2、R3和R4各自独立选自氢、烷基、杂烷基、环烷基、芳基环烷基、烯基、炔基、芳基、杂芳基、杂环烷基,所述
R1、R2和R3、R4各自可独立组合以形成杂环烷基,
R5和R6各自独立选自氢、羟基、巯基、烷氧基、硫代烷氧基、烷基、卤素、CN、CF3、NO2、COORD、CONRDRE、NRDRE、NRDCORE、NRDSO2RE、NRFCONRDRE;其中RD、RE和RF独立是氢、烷基、杂烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、环烷基和杂环烷基;
包括其所有药学上可接受的盐、酯、酰胺、立体异构体、几何异构体溶剂化物或前药。
32.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的权利要求31的化合物。
33.权利要求32的方法,其中所述癌是肉瘤。
34.权利要求32的方法,其中所述癌是癌瘤。
35.权利要求32的方法,其中所述癌选自结肠癌、腺癌、直肠癌、结直肠癌、乳癌、肺癌、卵巢癌、腺瘤性息肉病、肝细胞癌。
36.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表1-13的化合物。
37.权利要求36的方法,其中所述癌是肉瘤。
38.权利要求36的方法,其中所述癌是癌瘤。
39.权利要求36的方法,其中所述癌选自结肠癌、腺癌、直肠癌、结直肠癌、乳癌、肺癌、卵巢癌、腺瘤性息肉病、肝细胞癌。
40.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表1化合物。
41.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表2化合物。
42.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表3化合物。
43.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表4化合物。
44.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表5化合物。
45.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表6化合物。
46.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表7化合物。
47.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表8化合物。
48.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表9化合物。
49.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表10化合物。
50.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表11化合物。
51.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表12化合物。
52.一种在哺乳动物中预防、治疗或改善癌或肿瘤转移的方法,包括给予所述哺乳动物有效量的表13化合物。
53.一种基因集合,其中所述基因集合各成员的表达因权利要求31化合物的治疗而被调控。
54.权利要求53的基因集合,其中由于所述接触,所述基因集合各成员表达增加或所述基因集合各成员表达减少。
55.权利要求53的基因集合,其中所述基因集合成员选自表14限定的基因。
56.权利要求53的基因集合,其中所述基因集合存在于细胞中。
57.一种鉴定调控权利要求53的基因集合表达的药物的方法,包括:
(a)在其中表达所述基因集合成员的条件下使化合物与测试系统接触,所述测试系统含有与权利要求53基因集合各成员相对应的一种或多种多核苷酸;
(b)测定作为所述接触结果的步骤(a)所述一种或多种多核苷酸各自表达的改变;
其中在步骤(b)中所述表达的改变指示所述基因集合成员的调控,从而鉴定所述测试化合物是调控所述基因集合表达的药物。
58.权利要求57的方法,其中所述表达改变是所述一种或多种多核苷酸表达减少。
59.权利要求57的方法,其中所述表达改变是所述一种或多种多核苷酸转录改变。
60.权利要求57的方法,其中所述表达改变通过测定由所述多核苷酸编码的多肽活性的改变而确定。
61.权利要求57的方法,其中所述一种或多种多核苷酸存在于细胞中。
62.权利要求61的方法,其中所述细胞是癌细胞。
63.权利要求62的方法,其中所述癌细胞是结肠癌细胞。
64.权利要求63的方法,其中所述结肠癌细胞是腺癌癌细胞。
65.权利要求61的方法,其中所述细胞是经改造包含所述基因集合的重组细胞。
66.含有多个亚基因集合的基因集合,其中所述多个亚基因集合各自是通过权利要求57的方法鉴定的基因集合。
67.用权利要求57的方法鉴定为具有活性的化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810249295.4A CN108314663B (zh) | 2007-05-10 | 2008-05-09 | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92859207P | 2007-05-10 | 2007-05-10 | |
US60/928,592 | 2007-05-10 | ||
US99915307P | 2007-10-15 | 2007-10-15 | |
US60/999,153 | 2007-10-15 | ||
PCT/US2008/006015 WO2008140792A1 (en) | 2007-05-10 | 2008-05-09 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810249295.4A Division CN108314663B (zh) | 2007-05-10 | 2008-05-09 | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101730531A true CN101730531A (zh) | 2010-06-09 |
Family
ID=40002552
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810249295.4A Active CN108314663B (zh) | 2007-05-10 | 2008-05-09 | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 |
CN200880023589A Pending CN101730531A (zh) | 2007-05-10 | 2008-05-09 | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810249295.4A Active CN108314663B (zh) | 2007-05-10 | 2008-05-09 | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 |
Country Status (17)
Country | Link |
---|---|
US (3) | US8129519B2 (zh) |
EP (1) | EP2152258B1 (zh) |
JP (2) | JP5782586B2 (zh) |
KR (1) | KR101486026B1 (zh) |
CN (2) | CN108314663B (zh) |
AU (1) | AU2008251800B2 (zh) |
CA (2) | CA2686402C (zh) |
DK (1) | DK2152258T3 (zh) |
ES (1) | ES2584188T3 (zh) |
HU (1) | HUE029155T2 (zh) |
IL (2) | IL202039A (zh) |
MX (2) | MX2009011970A (zh) |
NZ (2) | NZ597731A (zh) |
PL (1) | PL2152258T3 (zh) |
PT (1) | PT2152258T (zh) |
WO (1) | WO2008140792A1 (zh) |
ZA (1) | ZA200907859B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103917514A (zh) * | 2011-11-06 | 2014-07-09 | 贝塔卡特药业有限公司 | 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法 |
CN106106481A (zh) * | 2016-06-16 | 2016-11-16 | 湖北工业大学 | 一种棉铃虫甾醇载体蛋白2抑制剂及其虚拟筛选方法 |
CN108137446A (zh) * | 2015-07-28 | 2018-06-08 | 贝塔卡特药业有限公司 | 蒽-9,10-二酮二肟化合物前药及其用途 |
CN117567385A (zh) * | 2023-11-23 | 2024-02-20 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向clec5a的小分子抑制剂及其应用 |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8129519B2 (en) * | 2007-05-10 | 2012-03-06 | Cholody Wieslaw M | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof |
CA2696288A1 (en) * | 2007-08-15 | 2009-02-19 | Schering Corporation | 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11.beta.-hydroxysteroid dehydrogenase type-1 |
EP2987487B1 (en) | 2009-08-10 | 2020-10-07 | Samumed, LLC | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
KR101161290B1 (ko) | 2009-10-16 | 2012-07-02 | 에스에프씨 주식회사 | 축합방향족화합물 및 이를 이용한 유기전계발광소자 |
CN102821607B (zh) | 2009-12-21 | 2014-12-17 | 萨穆梅德有限公司 | 1H-吡唑并[3,4-b]吡啶及其治疗应用 |
HUE041576T2 (hu) | 2011-09-14 | 2019-05-28 | Samumed Llc | Indazol-3-karboxamid-származékok és alkalmazásuk Wnt/b-katenin szignalizáló útvonal inhibitorokként |
US20130123281A1 (en) * | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
DK2770994T3 (da) | 2012-05-04 | 2019-11-11 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridiner og terapeutiske anvendelser deraf |
CA2897400A1 (en) | 2013-01-08 | 2014-07-17 | Samumed, Llc | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
EP3210144B1 (en) * | 2014-10-24 | 2020-10-21 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023996A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
WO2017023984A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023975A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
WO2017058716A1 (en) * | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
CN108472290A (zh) | 2015-11-06 | 2018-08-31 | 萨穆梅德有限公司 | 治疗骨关节炎 |
SG11201810683VA (en) | 2016-06-01 | 2018-12-28 | Samumed Llc | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
MX2019004616A (es) | 2016-10-21 | 2019-11-21 | Samumed Llc | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. |
WO2018085865A1 (en) | 2016-11-07 | 2018-05-11 | Samumed, Llc | Single-dose, ready-to-use injectable formulations |
WO2018118711A1 (en) | 2016-12-19 | 2018-06-28 | The Trustees Of Columbia University In The City Of New York | Small molecule ferroptosis inducers |
JP7159302B2 (ja) | 2017-06-02 | 2022-10-24 | イテリオン・セラピューティクス・インコーポレイテッド | 線維性疾患の治療のための方法 |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
US11136307B1 (en) * | 2020-09-29 | 2021-10-05 | Iterion Therapeutics, Inc. | Crystalline form of tegavivint, method of preparation, and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3044072A1 (de) * | 1980-11-24 | 1982-07-15 | Hoechst Ag, 6000 Frankfurt | Bis-aminomehtyl-anthrachinon-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
WO2002008193A2 (en) * | 2000-07-07 | 2002-01-31 | Cancer Research Technology Limited | Therapeutic acridone and acridine compounds |
US20040019042A1 (en) * | 2002-07-26 | 2004-01-29 | Chih-Hung Lee | Fluorenes and anthracenes that inhibit p2x3 and p2x2/3 containing receptors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627791A (en) * | 1968-11-21 | 1971-12-14 | Richardson Merrell Inc | Bis(aminoalkylsulfamoyl) anthraquinones |
US3983248A (en) | 1968-11-21 | 1976-09-28 | Richardson-Merrell Inc. | Bis(aminoalkylsulfamoyl)anthraquinone antiviral agents |
US3829578A (en) * | 1970-12-10 | 1974-08-13 | Richardson Merrell Inc | Antiviral compositions containing bis-basic ethers and thioethers of xanthene and xanthen-9-ones and methods of treating viruses therewith |
US3714194A (en) * | 1971-06-09 | 1973-01-30 | Upjohn Co | Di(azidosulfonyl)xanthones |
US3919211A (en) * | 1973-02-12 | 1975-11-11 | American Home Prod | 9-Oxoxanthene-N,N{40 -bis(substituted)-2,7-disulfonamides |
US3981248A (en) * | 1975-02-28 | 1976-09-21 | Hall Ski-Lift Company, Inc. | Timing gate for ski-lifts |
US4250097A (en) * | 1978-03-08 | 1981-02-10 | Syntex (U.S.A.) Inc. | Compositions for and a method of preventing diabetic complications |
US4251493A (en) * | 1978-07-21 | 1981-02-17 | Ciba-Geigy Corporation | Gas purification process |
IT1223302B (it) | 1987-09-16 | 1990-09-19 | Baldacci Lab Spa | Composti solfonamido derivati inibitori del sistema enzimatico aldoso-reduttasi e composizioni farmaceutiche che li contengono |
HUT67314A (en) * | 1993-04-09 | 1995-03-28 | Egyt Gyogyszervegyeszeti Gyar | Process for prepg. new trisubstituted cykloalkane deriv.s and pharmaceutical compn.s contg. them |
WO2002011574A1 (en) * | 2000-08-10 | 2002-02-14 | Benetton Group S.P.A. | Sports shoe |
CA2473170A1 (en) * | 2002-01-15 | 2003-07-24 | Cancer Research Technology Limited | Therapeutic acridone and acridine compounds |
WO2006113097A2 (en) * | 2005-04-15 | 2006-10-26 | The University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
US8129519B2 (en) * | 2007-05-10 | 2012-03-06 | Cholody Wieslaw M | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof |
-
2008
- 2008-05-09 US US12/451,313 patent/US8129519B2/en active Active
- 2008-05-09 ES ES08754344.3T patent/ES2584188T3/es active Active
- 2008-05-09 AU AU2008251800A patent/AU2008251800B2/en active Active
- 2008-05-09 MX MX2009011970A patent/MX2009011970A/es active IP Right Grant
- 2008-05-09 CN CN201810249295.4A patent/CN108314663B/zh active Active
- 2008-05-09 CN CN200880023589A patent/CN101730531A/zh active Pending
- 2008-05-09 EP EP08754344.3A patent/EP2152258B1/en active Active
- 2008-05-09 HU HUE08754344A patent/HUE029155T2/hu unknown
- 2008-05-09 PL PL08754344T patent/PL2152258T3/pl unknown
- 2008-05-09 WO PCT/US2008/006015 patent/WO2008140792A1/en active Application Filing
- 2008-05-09 NZ NZ597731A patent/NZ597731A/xx unknown
- 2008-05-09 NZ NZ581647A patent/NZ581647A/en unknown
- 2008-05-09 KR KR1020097025845A patent/KR101486026B1/ko active IP Right Grant
- 2008-05-09 MX MX2012009228A patent/MX354256B/es unknown
- 2008-05-09 DK DK08754344.3T patent/DK2152258T3/en active
- 2008-05-09 JP JP2010507482A patent/JP5782586B2/ja active Active
- 2008-05-09 PT PT87543443T patent/PT2152258T/pt unknown
- 2008-05-09 CA CA2686402A patent/CA2686402C/en active Active
- 2008-05-09 CA CA2871493A patent/CA2871493C/en active Active
-
2009
- 2009-11-09 ZA ZA2009/07859A patent/ZA200907859B/en unknown
- 2009-11-10 IL IL202039A patent/IL202039A/en active IP Right Grant
-
2012
- 2012-01-30 US US13/361,761 patent/US9120754B2/en active Active
-
2014
- 2014-03-27 JP JP2014066444A patent/JP6352017B2/ja active Active
-
2015
- 2015-01-21 IL IL236827A patent/IL236827A/en active IP Right Grant
- 2015-07-09 US US14/795,709 patent/US9446021B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3044072A1 (de) * | 1980-11-24 | 1982-07-15 | Hoechst Ag, 6000 Frankfurt | Bis-aminomehtyl-anthrachinon-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
WO2002008193A2 (en) * | 2000-07-07 | 2002-01-31 | Cancer Research Technology Limited | Therapeutic acridone and acridine compounds |
US20040019042A1 (en) * | 2002-07-26 | 2004-01-29 | Chih-Hung Lee | Fluorenes and anthracenes that inhibit p2x3 and p2x2/3 containing receptors |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103917514A (zh) * | 2011-11-06 | 2014-07-09 | 贝塔卡特药业有限公司 | 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法 |
CN103917514B (zh) * | 2011-11-06 | 2016-11-16 | 贝塔卡特药业有限公司 | 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法 |
CN108137446A (zh) * | 2015-07-28 | 2018-06-08 | 贝塔卡特药业有限公司 | 蒽-9,10-二酮二肟化合物前药及其用途 |
CN106106481A (zh) * | 2016-06-16 | 2016-11-16 | 湖北工业大学 | 一种棉铃虫甾醇载体蛋白2抑制剂及其虚拟筛选方法 |
CN106106481B (zh) * | 2016-06-16 | 2019-06-28 | 湖北工业大学 | 一种棉铃虫甾醇载体蛋白2抑制剂及其虚拟筛选方法 |
CN117567385A (zh) * | 2023-11-23 | 2024-02-20 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向clec5a的小分子抑制剂及其应用 |
CN117567385B (zh) * | 2023-11-23 | 2024-04-30 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向clec5a的小分子抑制剂及其应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101730531A (zh) | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 | |
KR101444489B1 (ko) | 심혈관 질환을 예방 및 치료하기 위한 화합물 | |
DK2998296T3 (en) | CYCLOYLIC ACID DERIVATIVE, PROCEDURE FOR PREPARING THEREOF AND PHARMACEUTICAL USE THEREOF | |
CA2998034C (en) | A group of compounds used for the treatment or prevention of hyperuricemia or gout | |
WO2021147879A1 (zh) | Shp2抑制剂及其应用 | |
AU2014240003B2 (en) | Coumarin derivatives and methods of use in treating hyperproliferative diseases | |
JP2021523887A (ja) | XIIa因子インヒビター | |
JP2022070895A (ja) | ニューロキニン-1受容体アンタゴニストとしての化合物およびその使用 | |
CN110891568A (zh) | 用于治疗冠状动脉病症的短链脱氢酶活性的抑制剂 | |
WO2014145512A2 (en) | Potent small molecule inhibitors of autophagy, and methods of use thereof | |
WO2010078711A1 (zh) | 氨基甲醇衍生物及其盐类化合物及其合成方法和其药物用途 | |
JP2024516040A (ja) | キサンチンオキシダーゼ抑制剤 | |
EP3296294A1 (en) | Compound for treating or preventing breast cancer | |
JP2021509399A (ja) | インドールアミン−2,3−ジオキシゲナーゼ阻害剤およびその調製方法と使用 | |
US6255298B1 (en) | Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases | |
KR20190017890A (ko) | 할로겐화 화합물 및 이의 축상 키랄성 이성질체 | |
RU2420513C2 (ru) | Соединения для лечения заболеваний, опосредованных липазой | |
KR20120122705A (ko) | 혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법 | |
US20240025845A1 (en) | Metastasis-inhibiting composition of novel methylsulfonamide derivative compound | |
WO2015157145A1 (en) | Iodonium analogs as inhibitors of nadph oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | |
US7355055B2 (en) | Compounds for treatment of lipase-mediated diseases | |
US20230045031A1 (en) | Diarylamide Compound and Application Thereof | |
JPS6160656A (ja) | ロイコトリエン拮抗剤 | |
WO2013027801A1 (ja) | 縮合へテロ環誘導体及びその医薬用途 | |
CN113891749A (zh) | 喹啉衍生物及其用于治疗癌症的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1150359 Country of ref document: HK |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100609 |
|
RJ01 | Rejection of invention patent application after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1150359 Country of ref document: HK |